BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

174 related articles for article (PubMed ID: 21397985)

  • 21. Radical prostatectomy for clinically advanced (cT3) prostate cancer since the advent of prostate-specific antigen testing: 15-year outcome.
    Ward JF; Slezak JM; Blute ML; Bergstralh EJ; Zincke H
    BJU Int; 2005 Apr; 95(6):751-6. PubMed ID: 15794776
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Long-term risk of clinical progression after biochemical recurrence following radical prostatectomy: the impact of time from surgery to recurrence.
    Boorjian SA; Thompson RH; Tollefson MK; Rangel LJ; Bergstralh EJ; Blute ML; Karnes RJ
    Eur Urol; 2011 Jun; 59(6):893-9. PubMed ID: 21388736
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Identification of factors predicting response to adjuvant radiation therapy in patients with positive margins after radical prostatectomy.
    Kamat AM; Babaian K; Cheung MR; Naya Y; Huang SH; Kuban D; Babaian RJ
    J Urol; 2003 Nov; 170(5):1860-3. PubMed ID: 14532793
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Avoidance and management of positive surgical margins before, during and after radical prostatectomy.
    Bott SR; Kirby RS
    Prostate Cancer Prostatic Dis; 2002; 5(4):252-63. PubMed ID: 12627209
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Outcome of adjuvant radiotherapy after radical prostatectomy for prostate cancer patients.
    Suzuki K; Nakano K; Morita T
    Urol Int; 2010; 84(4):382-7. PubMed ID: 20224263
    [TBL] [Abstract][Full Text] [Related]  

  • 26. The relationship between the extent of surgical margin positivity and prostate specific antigen recurrence in radical prostatectomy specimens.
    Marks RA; Koch MO; Lopez-Beltran A; Montironi R; Juliar BE; Cheng L
    Hum Pathol; 2007 Aug; 38(8):1207-11. PubMed ID: 17490720
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Is anastomotic biopsy necessary before radiotherapy after radical prostatectomy?
    Koppie TM; Grossfeld GD; Nudell DM; Weinberg VK; Carroll PR
    J Urol; 2001 Jul; 166(1):111-5. PubMed ID: 11435834
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Prognostic significance of preoperative factors in localized prostate carcinoma treated with radical prostatectomy: importance of percentage of biopsies that contain tumor and the presence of biopsy perineural invasion.
    Quinn DI; Henshall SM; Brenner PC; Kooner R; Golovsky D; O'Neill GF; Turner JJ; Delprado W; Grygiel JJ; Sutherland RL; Stricker PD
    Cancer; 2003 Apr; 97(8):1884-93. PubMed ID: 12673714
    [TBL] [Abstract][Full Text] [Related]  

  • 29. [Progression after radical prostatectomy of cancer of the prostate: prognostic criteria and the role of PSA in monitoring].
    Fendler JP; Dujardin T; Bringeon G; Adeleine P; Devonec M; Perrin P
    Prog Urol; 1992 Feb; 2(1):58-65. PubMed ID: 1284386
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Is preoperative serum prostate-specific antigen level significantly related to clinical recurrence after radical retropubic prostatectomy for localized prostate cancer?
    Haukaas SA; Halvorsen OJ; Daehlin L; Hostmark J; Akslen LA
    BJU Int; 2006 Jan; 97(1):51-5. PubMed ID: 16336328
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Long-term outcome of patients with prostate cancer and pathologic seminal vesicle invasion (pT3b): effect of adjuvant radiotherapy.
    Lee HM; Solan MJ; Lupinacci P; Gomella LG; Valicenti RK
    Urology; 2004 Jul; 64(1):84-9. PubMed ID: 15245941
    [TBL] [Abstract][Full Text] [Related]  

  • 32. The outcome of patients with pathological Gleason score >or=8 prostate cancer after radical prostatectomy.
    Rodriguez-Covarrubias F; Larre S; De La Taille A; Abbou CC; Salomon L
    BJU Int; 2008 Feb; 101(3):305-7. PubMed ID: 17941921
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Oncological and functional results of antegrade radical retropubic prostatectomy for the treatment of clinically localised prostate cancer.
    Carini M; Masieri L; Minervini A; Lapini A; Serni S
    Eur Urol; 2008 Mar; 53(3):554-61. PubMed ID: 17683854
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Perineural invasion as a predictor of biochemical outcome following radical prostatectomy for select men with clinically localized prostate cancer.
    D'Amico AV; Wu Y; Chen MH; Nash M; Renshaw AA; Richie JP
    J Urol; 2001 Jan; 165(1):126-9. PubMed ID: 11125380
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Outcomes of radical prostatectomy in clinically locally advanced N0M0 prostate cancer.
    Mearini L; Zucchi A; Costantini E; Bini V; Nunzi E; Porena M
    Urol Int; 2010; 85(2):166-72. PubMed ID: 20558980
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Long-term outcome after radical prostatectomy for patients with lymph node positive prostate cancer in the prostate specific antigen era.
    Boorjian SA; Thompson RH; Siddiqui S; Bagniewski S; Bergstralh EJ; Karnes RJ; Frank I; Blute ML
    J Urol; 2007 Sep; 178(3 Pt 1):864-70; discussion 870-1. PubMed ID: 17631342
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Loose seeds versus stranded seeds in I-125 prostate brachytherapy: differences in clinical outcome.
    Hinnen KA; Moerland MA; Battermann JJ; van Roermund JG; Monninkhof EM; Jürgenliemk-Schulz IM; van Vulpen M
    Radiother Oncol; 2010 Jul; 96(1):30-3. PubMed ID: 20215039
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Does prior benign prostate biopsy predict outcome for patients treated with radical perineal prostatectomy?
    Raj GV; Brashears JH; Anand A; Paulson DF; Polascik TJ
    Urology; 2005 Feb; 65(2):332-6. PubMed ID: 15708048
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Prostate-specific antigen control with low-dose adjuvant radiotherapy for high-risk prostate cancer.
    Macdonald OK; Lee RJ; Snow G; Lee CM; Tward JD; Middleton AW; Middleton GW; Sause WT
    Urology; 2007 Feb; 69(2):295-9. PubMed ID: 17320667
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Radial distance of extraprostatic extension measured by ocular micrometer is an independent predictor of prostate-specific antigen recurrence: A new proposal for the substaging of pT3a prostate cancer.
    Sung MT; Lin H; Koch MO; Davidson DD; Cheng L
    Am J Surg Pathol; 2007 Feb; 31(2):311-8. PubMed ID: 17255778
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.